Ratio Therapeutics is a clinical-stage pharmaceutical company that systematically engineers radiopharmaceuticals using its Trillium pharmacokinetic tuning technology and Macropa chelator platform. Its lead program, [Ac-225]RTX-2358, is in the ATLAS Phase 1/2 trial, and the broader pipeline includes a next-generation GRPR program, additional mono- and bispecific radioligand therapies, and imaging assets. The company has demonstrated external validation through partnered programs, including a collaboration with Novartis on an SSTR2 radioligand therapy. Ratio operates a hybrid manufacturing model with a vertically integrated manufacturing site in Utah, external partners, and diversified isotope supply. Financially, the company recently closed a $70 million Series C that brings total capital raised to over $240 million. Planned near-term activities include advancing the ATLAS trial, filing its fifth IND, moving the next-generation RLT into the clinic, expanding target indications, and scaling manufacturing to support future commercial demand.

Total raised

$160M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2026